After over 10 years of basic and clinical research, Professor Jin Shengwei's team innovatively suggested that the obstruction of inflammation subsides obstacle is a new mechanism of acute respiratory distress syndrome. It initially tested that the decline of lipoxygenin and recedisin is the key factor of the obstruction of inflammation subsides, and established a dynamic detection system of promoting inflammation subsides medium (lipoxin, resolvin), coupled with high efficiency liquid chromatography and mass spectrum. The system, as an indicator of disease early warning, diagnosis, curative effect and prognosis, is used to screen for the prevention and control of acute respiratory distress syndrome (ACS) with an up-regulated medium (lipoxin, resolvin).
The project was funded by 9 National Natural Science Foundation, and 162 papers were published, of which 63 were collected in SCI, totally 218 impact factors and cited 830 times. The European SSC Guide cited the findings of the project as 1B evidence. The chief executive of the project, as the president of the conference, presided the academic conference on international acute respiratory distress syndrome 4 times. The project team was invited to orally report on the results on the “new strategy for promoting the treatment of inflammation subsides” on the International Conference 17 times, and the results were successively promoted and applied by more than 20 major medical units, including the Affiliated Hospital of Huazhong University of Science and Technology, Shandong Provincial Hospital,which made the incidence of acute respiratory distress syndrome in high risk population decreased by 17%; and the mortality rate of 1557 patients with acute respiratory distress syndrome was reduced by 8%, obtaining satisfied curative effect and good social evaluation.
It is acknowledged that pancreatic carcinoma is the king of carcinoma. Currently lacking early diagnosis and effective treatment, the survival rate within five years is less than 5%. There exist difficulties in diagnosis and treatment, such as difficult early detection, rapid precancerous lesion, low radical resection rate, easy drug resistance and poor efficacy. The main reason is that the malignant degree of biological behavior is very high. Therefore, reducing the malignant degree of biological behavior can improve the curative effect.
Professor Zhou Mengtao's team regarded reducing the malignancy of biological behavior to prolong life as a goal oriented, focusing on the biological new technology that reverses pancreatic cancer resistance for over ten years, and innovatively put forward the theory of “biological behavior oriented diagnosis and treatment of pancreatic cancer”, which has created a series of prominent “reversing resistance” and “plant extract treatment”. The new technology of diagnosis and treatment, such as “extract treatment” and “gene intervention” has achieved the goal of improving curative effect, and provided new ideas for the treatment of pancreatic cancer.
A total of 59 papers were published in the project, including 29 collected in SCI, with a total impact factor of 79.1, an average of 2.73; and 11 Zhonghua brand magazines. It was cited by others in SCI 183 times, of which was cited by Nature Reviews Cancer (IF=37.4), Genome Res, and cited 37times on authoritative journals (IF>=5.0), most single cited up to 51 times. It obtained a National Invention Patent. The chief editor has published 12 monographs and tutored 23 postgraduates and doctoral students, as well as held two stages of continuing study class. The project has achieved satisfied curative effect in 18 hospitals, involving Wuhan Union Hospital, Sino-Japan Friendship Hospital Affiliated to Jilin University, and Zhejiang University, etc.